Allosteric nicotinic receptors, human pathologies

Journal of Physiology Paris

Volumn 92, Issue 2, 1998, Pages 63-74

  Léna, Clément ^a   Changeux, Jean Pierre ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Allosteric proteins; Alzheimer's disease; Congenital myasthenia; Frontal lobe epilepsy; Nicotine addiction; Nicotinic acetylcholine receptors; Schizophrenia

Indexed keywords

ACETYLCHOLINE; ALPHA BUNGAROTOXIN; HALOPERIDOL; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR;

ALZHEIMER DISEASE; CHANNEL GATING; CHOLINERGIC SYSTEM; CONFERENCE PAPER; DOPAMINERGIC NERVE CELL; FRONTAL LOBE EPILEPSY; GILLES DE LA TOURETTE SYNDROME; MYASTHENIA GRAVIS; PATHOGENESIS; PLEIOTROPY; POINT MUTATION; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; SCHIZOPHRENIA; SMOKING;

EID: 0032458934     PISSN: 09284257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4257(98)80140-X     Document Type: Conference Paper

References (112)

1. [1] Léna C., Changeux J.P., Pathological mutations of nicotinic receptors and nicotine-based therapies for brain disorders, Curr. Opin. Neurobiol. 7 (1997) 674-682.
2. [2] Changeux J.P., Kasai M., Lee C.Y., The use of a snake venom toxin to characterize the cholinergic receptor protein, Proc. Natl. Acad. Sci. USA 67 (1970) 1241-1247.
3. [3] Changeux J.P., The acetylcholine receptor: an 'allosteric' membrane protein, in: Harvey Lectures, Academic Press Inc., 1981, pp. 85-254.
4. [4] Nachmansohn D., Chemical and molecular basis of nerve activity, Academic Press New York, 1959.
5. [5] Lee C.Y., Chang C.C., Modes of actions of purified toxins from elapid venoms on neuromuscular transmission, Mem. Inst. Butantan Sao Paulo, 33 (1966) 555-572.
6. [6] Numa S., A molecular view of neurotransmitter receptors and ionic channels, Harvey Lecture Series 83 (1989) 121-165.
7. [7] Heinemann S., Boulter J., Deneris E., Connolly J., Gardner P., Wada E., Wada K., Duvoisin R., Ballivet M., Swanson L., Patrick J., Brain and muscle nicotinic acetylcholine receptor: a gene family., in: Maelicke A. (Ed.), Molecular Biology of Neuroreceptors and Ion Channels, Springer-Verlag, Berlin Heidelberg, 1989, pp. 13-30.
8. [8] Galzi J.L., Changeux J.P., Neuronal nicotinic receptors: molecular organization and regulations, Neuropharmacology 34 (1995) 563-582.
9. [9] Role L.W., Berg D.K., Nicotinic receptors in the development and modulation of CNS synapses, Neuron 16 (1996) 1077-1085.
10. [10] Le Novère N., Changeux J.P., Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells, J. Mol. Evol. 40 (1995) 155-172.
11. [11] Corringer P.J., Galzi J.L., Eiselé J.L., Bertrand S., Changeux J.P., Bertrand D., Identification of a new component of the agonist binding site of the nicotinic alpha 7 homooligomeric receptor, J. Biol. Chem. 270 (1995) 11749-11752.
12. [12] Tsigelny I., Sugiyama N., Sine S.M., Taylor P., A model of the nicotinic receptor extracellular domain based on sequence identity and residue location, Biophys. J. 73 (1997) 52-66.
13. [13] Karlin A., Akabas M.H., Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins, Neuron 15 (1995) 1231-1244.
14. [14] Corringer P.J., Bertrand S., Bohler S., Edelstein S.J., Changeux J.P., Critical elements determining diversity in agonsit binding and desensitization of neuronal nicotinic acetylcholine receptors, J. Neurosci. 18 (1998) 648-657.
15. 3H]-chlorpromazine, Proc. Natl. Acad. Sci.USA 83 (1986) 2719-2723.
16. 3H] chlorpromazine labels homologous residues in the beta and delta chains. Biochemistry 26 (1987) 2410-2418.
17. [17] Hucho F., Oberthür W., Lottspeich F., The ion channel of the nicotinic acetylcholine receptor is formed by the homologous helices M2 of the receptor subunits, FEBS Lett. 205 (1986) 137-142.
18. [18] Leonard R.J., Labarca C.G., Charnet P., Davidson N., Lester H.A., Evidence that the M2 membrane-spanning region lines the ion channel pore of the nicotinic receptor, Science 242 (1988) 1578-1581.
19. [19] Imoto K., Methfessel C., Sakmann B., Mishina M., Mori Y., Konno T., Fukuda K., Kurasaki M., Bujo H., Fujita Y., Numa S., Location of a delta-subunit region determining ion transport through the acetylcholine receptor channel. Nature 324 (1986) 670-674.
20. [20] Imoto K., Busch C., Sakmann B., Mishina M., Konno T., Nakai J., Bujo H., Mori Y., Fukuda K., Numa S., Rings of negatively charged amino acids determine the acetylchoine receptor channel conductance, Nature 335 (1988) 645-648.
21. [21] Cohen J.B., Blanton M.P., Chiara D.C., Sharp S.D., White B.H., Structural organization of functional domains of the nicotinic acetylcholine receptor, J. Biol. Chem. 3 (1992) 217.
22. [22] Bertrand D., Galzi J.L., Devillers-Thiery A., Bertrand S., Changeux J.P., Mutations at two distinct sites within the channel domain M2 alter calcium permeability of neuronal alpha7 nicotinic receptor, Proc. Natl. Acad. Sci. USA 90 (1993) 6971-6975.
23. [23] Gotti C., Fornasari D., Clementi F., Human neuronal nicotinic receptors, Prog. Neurobiol. 53 (1997) 199-237.
24. [24] McGehee D.S., Role L.W., Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons, Annu. Rev. Physiol. 57 (1995) 521-546.
25. [25] Fucile S., Matter J.M., Erkman L., Ragozzino D., Barabino B., Grassi F., Alema S., Ballivet M., Eusebi F., The neuronal alpha6 subunit forms functional heteromeric acetylcholine receptors in human transfected cells, Eur. J. Neurosci. 10 (1998) 172-178.
26. [26] Ramirez Latorre J., Yu C.R., Qu X., Perin F., Karlin A., Role L., Functional contributions of alpha5 subunit to neuronal acetylcholine receptor channels, Nature 380 (1996) 347-351.
27. [27] Wang F., Gerzanich V., Wells G.B., Anand R., Peng X., Keyser K., Lindstrom J., Assembly of human neuronal nicotinic receptor alpha5 subunits with alpha3, beta2, and beta4 subunits, J. Biol. Chem. 271 (1996) 17656-17665.
28. [28] Le Novère N., Zoli M., Changeux J.P., Neuronal nicotinic receptor alpha6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain, Eur. J. Neurosci. 8 (1996) 2428-2449.
29. [29] Rogers M., Colquhoun L.M., Patrick J.W., Dani J., Calcium flux through predominantly independent purinergic ATP and nicotinic acetylcholine receptors, J. Neurophysiol. 77 (1997) 1407-1417.
30. [30] Changeux J.P., Functional architecture and dynamics of the nicotinic acetylcholine receptor: an allosteric ligand-gated ion channel, in: Changeux J.P. et al. (Eds.), Fidia Research Foundation Neuroscience Award Lectures, Raven Press Ltd., New York. 1990, pp. 21-168.
31. [31] Edelstein S.J., Schaad O., Henry E., Bertrand D., Changeux J.P., A kinetic mechanism for nicotinic acetylcholine receptors based on multiple allosteric transitions, Biol. Cybern. 75 (1996) 361-379.
32. [32] Peng X., Katz M., Gerzanich V., Anand R., Lindstrom J., Human alpha7 acetylcholine receptor: cloning of the alpha7 subunit from the SH-SY5Y cell line and determination of pharmacological properties of native receptors and functional alpha7 homomers expressed in Xenopus oocytes, Mol. Pharmacol. 45 (1994) 546-554.
33. [33] Gerzanich V., Peng X., Wang F., Wells G., Anand R., Fletcher S., Lindstrom J., Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors, Mol. Pharmacol. 48 (1995) 774-782.
34. [34] Gopalakrishnan M., Buisson B., Touma E., Giordano T., Campbell J.E., Hu I.C., Donnelly R.D., Arneric S.P., Bertrand D., Sullivan J.P., Stable expression and pharmacological properties of the human alpha7 nicotinic acetylcholine receptor, Eur. J. Pharmacol. 290 (1995) 237-246.
35. [35] Buisson B., Gopalakrishnan M., Arneric S.P., Sullivan J.P., Bertrand D., Human alpha4beta2 neuronal nicotinic acetylcholine receptor in HEK 293 cells: A patch-clamp study, J. Neurosci. 16 (1996) 7880-7891.
36. [36] Chavez Noriega L.E., Crona J.H., Washburn M.S., Urrutia A., Elliott K.J., Johnson E.C., Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h-alpha2beta2, h-alpha2beta4, h-alpha3beta2, h-alpha3beta4, h-alpha4beta2, h-alpha beta4 and h-alpha7 expressed in Xenopus oocytes, J. Pharmacol. Exp. Ther. 280 (1997) 346-356.
37. [37] Edelstein S.J., Schaad O., Changeux J.P., Mytasthenic nicotinic receptor mutant interpreted in terms of the allosteric model, C. R. Acad. Sci. Paris 320 (1997) 953-961.
38. [38] Edelstein S., Schaad O., Changeux J.P., Single binding versus single channel recordings: a new approach to study ionotropic receptors, Biochemistry 36 (1997) 13755-13760.
39. [39] Revah F, Bertrand D., Galzi J.L., Devillers-Thiery A., Mulle C., Hussy N., Bertrand S., Ballivet M., Changeux J.P., Mutations in the channel domain alter desensitization of a neuronal nicotinic receptor, Nature 353 (1991) 846-849.
40. [40] Galzi J.L., Bertrand D., Devillers-Thiery A., Revah F., Bertrand S., Changeux J.P., Functional significance of aromatic amino acids from three peptide loops of the alpha7 neuronal nicotinic receptor site investigated by site-directed mutagenesis, FEBS Lett. 294 (1991) 198-202.
41. [41] Devillers-Thiery A., Galzi J.L., Bertrand S., Changeux J.P., Bertrand D., Stratified organization of the nicotinic acetylcholine receptor channel, Neuroreport 3 (1992) 1001-1004.
42. [42] Bertrand D., Devillers-Thiery A., Revah F., Galzi J.L., Hussy N., Mulle C., Bertrand S., Ballivet M., Changeux J.P., Unconventional pharmacology of a neuronal nicotinic receptor mutated in the channel domain, Proc. Natl. Acad. Sci. USA 89 (1992) 1261-1265.
43. [43] Labarca C., Nowak M.W., Zhang H., Tang L., Deshpande R, Lester H.A., Channel gating governed symmetrically by conserved leucine residues in the M2 domain of nicotinic receptors, Nature 376 (1995) 514-516.
44. [44] Galzi J.L., Edelstein S.J., Changeux J., The multiple phenotypes of allosteric receptor mutants, Proc. Natl. Acad. Sci. USA 93 (1996) 1853-1858.
45. [45] Zoli M., Le Novere N., Hill J.J., Changeux J.P., Developmental regulation of nicotinic ACh receptor subunit mRNAs in the rat central and peripheral nervous systems, J. Neurosci. 15 (1995) 1912-1939.
46. [46] Picciotto M.R., Zoli M., Léna C., Bessis A., Lallemand Y., Le Novere N., Vincent P., Merlo Pich E., Brûlet P., Changeux J.P., Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain, Nature 374 (1995) 65-67.
47. [47] Zoli M., Léna C., Picciotto M.R., Changeux J.P., Identification of four classes of brain nicotinic receptors using beta2 mutant mice, J. Neurosci. 18 (1998), 4461-4472.
48. 125I] α-bungarotoxin, J. Neurosci. 5 (1985) 1307-1313.
49. 3H]epibatidine labels nicotinic receptors in rat brain: an autoradiographic study, J. Pharmacol. Exp. Ther. 275 (1995) 1030-1034.
50. [50] Orr-Urtreger A., Goldner F.M., Saeki M., Lorenzo I., Goldberg L., De Biasi M., Dani J.A., Patrick J.W., Beaudet A., Mice deficient in the alpha7 neuronal nicotinic acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast nicotinic currents, J. Neurosci. 17 (1997) 9165-9171.
51. [51] Changeux J.P., Bessis A., Bourgeois J.P., Corringer P.J., Devillers-Thiery A., Eisele J.L., Kerszberg M., Lena C., Le Novere N., Picciotto M., Zoli M., Nicotinic receptors and brain plasticity, Cold Spring Harb. Symp. Quant. Biol. 61 (1996) 343-362.
52. [52] Treinin M., Chalfie M., A mutated acetylcholine receptor subunit causes neuronal degeneration in C. elegans, Neuron 14 (1995) 871-877.
53. [53] Ohno K., Wang H.L., Milone M., Bren N., Brengman J.M., Nakano S., Quiram P., Pruitt J.N., Sine S.M., Engel A.G., Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor epsilon subunit, Neuron 17 (1996) 157-170.
54. [54] Ohno K., Quiram P.A., Milone M., Wang H.L., Harper M.C., Pruitt J.N., Brengman J.M., Pao L., Fischbeck K.H., Crawford T.O., Sine S.M., Engel A.G., Congenital myasthenic syndromes due to heteroallelic nonsense/missense mutations in the acetylcholine receptor epsilon subunit gene - identification and functional characterization of six new mutations, Hum. Mol. Genet. 6 (1997) 753-766.
55. [55] Milone M., Wang H.L., Ohno K., Prince R., Fukudome T., Shen X.M., Brengman J.M., Griggs R.C., Sine S.M., Engel A.G., Mode switching kinetics produced by a naturally occuring mutation in the cytoplasmic loop of the human acetylcholine receptor epsilon subunit, Neuron 20 (1998) 575-588.
56. [56] Engel A.G., Ohno K., Bouzat C., Sine S.M., Griggs R.C., End-plate acetylcholine receptor deficiency due to nonsense mutations in the epsilon subunit, Ann. Neurol. 40 (1996) 810-817.
57. [57] Witzemann V., Schwarz H., Koenen M., Berberich C., Villarroel A., Wernig A., Brenner H.R., Sakmann B., Acetylcholine receptor epsilon-subunit deletion causes muscle weakness and atrophy in juvenile and adult mice, Proc. Natl. Acad. Sci. USA 93 (1996) 13286-13291.
58. [58] Ohno K., Hutchinson D.O., Milone M., Brengman J.M., Bouzat C., Sine S.M., Engel A.G., Congenital myasthenic syndrome caused by prolonged acetylcholine receptor channel openings due to a mutation in the M2 domain of the epsilon subunit, Proc. Natl. Acad. Sci. USA 92 (1995) 758-762.
59. [59] Sine S.M., Ohno K., Bouzat C., Auerbach A., Milone M., Pruitt J.N., Engel A.G., Mutation of the acetylcholine receptor alpha subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity, Neuron 15 (1995) 229-239.
60. [60] Engel A.G., Ohno K., Milone M., Wang H.L., Nakano S., Bouzat C., Pruitt J.N. 2nd., Hutchinson D.O., Brengman J.M., Bren N., Sieb J.P., Sine S.M., New mutations in acetykholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. Hum. Mol. Genet. 5 (1996) 1217-1227.
61. [61] Gomez C.M., Maselli R., Gammack J., Lasalde J., Tamamizu S., Cornblath D.R., Lehar M., McNamee M., Kuncl R.W., A beta-subunit mutation in the acetylcholine receptor channel gate causes severe slow-channel syndrome, Ann. Neurol. 39 (1996) 712-723.
62. [62] Croxen R., Newland C., Beeson D., Oosterhuis H., Chauplannaz G., Viacent A., Newsom-Davis J., Mutations in different functional domains of the human muscle acetylcholine receptor alpha subunit in patients with the slow-channel congenital myasthenic syndrome, Hum. Mol. Genet. 6 (1997) 767-774.
63. [63] Milone M., Wang H., Ohno K., Fukudome T., Pruitt J., Bren N., Sine S., Engel A., Slow-channel myasthenic syndrome caused by enhanced activation, desensitization and agonist binding affinity attributable to mutation in the M2 domain of acetylcholine receptor alpha subunit, J. Neurosci. 17 (1997) 5651-5665.
64. [64] Edelstein S.J., Changeux J.P., Allosteric proteins after thirty years: the binding and state functions of the neuronal alpha7 nicotinic acetylcholine receptors, Experientia 52 (1996) 1083-1090.
65. [65] Gomez C.M., Maselli R., Gundeck J.E., Chao M., Day J.W., Tamamizu S., Lasalde J.A., McNamee M., Wollmann R.L., Slow-channel transgenic mice - a model of postsynaptic organellar degeneration at the neuromuscular junction, J. Neurosci. 17 (1997) 4170-4179.
66. [66] Steinlein O.K., Mulley J.C., Propping P., Wallace R.H., Phillips H.A., Sutherland G.R., Scheffer I.E., Berkovic S.F., A missense mutation in the neuronal nicotinic acetylcholine receptor alpha4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy, Nat. Genet. 11 (1995) 201-203.
67. [67] Weiland S., Witzemann V., Villarroel A., Propping P., Steinlein O., An amino acid exchange in the second transmembrane segment of a neuronal nicotinic receptor causes partial epilepsy by altering its desensitization kinetics. FEBS Lett. 398 (1996) 91-96.
68. 2+ permeability, conductance, and gating of human alpha4beta2 nicotinic acetylcholine receptors, J. Neurosci. 17 (1997) 9035-9047.
69. [69] Steinlein O.K., Magnusson A., Stoodt J., Bertrand S., Weiland S., Berkovic S.F., Nakken K.O., Propping P., Bertrand D., An insertion mutation of the CHRNA4 gene in a family with autosomal dominant nocturnal frontal lobe epilepsy, Hum. Mol. Genet. 6 (1997) 943-947.
70. [70] Lynch J.W., Rajendra S., Pierce K.D., Handford C.A., Barry P.H., Schofield P.R., Identification of intracellular and extracellular domains mediating signal transduction in the inhibitory glycine receptor chloride channel, EMBO J. 16 (1997) 110-120.
71. 2+ ions in nicotinic facilitation of GABA release in mouse thalamus, J. Neurosci. 17 (1997) 576-585.
72. [72] Orr Urtreger A., Noebels J.L., Goldner F.M., Patrick J., Beaudet A.L., A novel hypersynchronous neocortical EEG phenotype in mice deficient in the neuronal nicotinic acetylcholine receptor (nAChRs) alpha7 subunit gene, Am. J. Hum. Genet. 59 (1996) A53.
73. [73] Bierer L.M., Haroutunian V., Gabriel S., Knott P.J., Carlin L.S., Purohit D.P., Perl D.P., Schmeidler J., Kanof P., Davis K.L., Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits, J. Neurochem. 64 (1995) 749-760.
74. [74] Perry E.K., Morris C.M., Court J.A., Cheng A., Fairbairn A.F., McKeith I.G., Irving D., Brown A., Perry R.H., Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology, Neuroscience 64 (1995) 385-395.
75. [75] Newhouse P.A., Sunderland T., Tariot P.N., Blumhardt C.L., Weingartner H., Mellow A., Murphy D.L., Intravenous nicotine in Alzheimer's disease: a pilot study, Psychopharmacology 95 (1988) 171-175.
76. [76] Jones G.M., Sahakian B.J., Levy R., Warburton D.M., Gray J.A., Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease, Psychopharmacology 108 (1992) 485-494.
77. [77] Marchi M., Raiteri M., Nicotinic autoreceptors mediating enhancement of acetylcholine release become operative in conditions of 'impaired' cholinergic presynaptic function, J. Neurochem. 67 (1996) 1974-1981.
78. [78] Arneric S.P., Sullivan J.P., Decker M.W., Brioni J.D., Bannon A.W., Briggs C.A., Donnelly R.D., Radek R.J., Marsh K.C., Kyncl J., et al., Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties, Alzheimer Dis. Assoc. Disord. 2 (1995) 50-61.
79. [79] Cosford N.D., Bleicher L., Herbaut A., McCallum J.S., Vernier J.M., Dawson H., Whitten J.P., Adams P., Chavez N.L., Correa L.D., Crona J.H., Mahaffy L.S., Menzaghi F., Rao T.S., Reid R., Sacaan A.I., Santori E., Stauderman K.A., Whelan K., Lloyd G.K., McDonald I.A., (S)-(-)-5-ethynyl3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors, J. Med. Chem. 39 (1996) 3235-3237.
80. [80] Lippiello P.M., Bencherif M., Gray J.A., Peters S., Grigoryan G., Hodges H., Collins A.C., RJR-2403: a nicotinic agonist with CNS selectivity II. In vivo characterization, J. Pharmacol. Exp. Ther. 279 (1996) 1422-1429.
81. [81] Dehaene S., Changeux J.P., The Wisconsin Card Sorting Test: theoretical analysis and modeling in a neuronal network, Cereb. Cortex 1 (1991) 62-79.
82. [82] Pennartz C., The ascending neuromodulatory systems in learning by reinforcement -comparing computational conjectures with experimental findings, Brain Res. Brain Res. Rev. 21 (1996) 219-245.
83. [83] Altman J., Everitt B.J., Glautier S., Markou A., Nutt D., Oretti R., Phillips G.D., Robbins T.W., The biological, social and clinical bases of drug addiction: commentary and debate, Psychopharmacology 125 (1996) 285-345.
84. [84] Rose J.E., Corrigall W.A., Nicotine self-administration in animals and humans - similarities and differences, Psychopharmacology 130 (1997) 28-40.
85. [85] Pontieri F.E., Tanda G., Orzi F., Di Chiara G., Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs, Nature 382 (1996) 255-257.
86. [86] Merlo Pich E., Pagliusi S.R., Tessari M., Talabot-Ayer D., Hooft van Huijsduijnen R., Chiamulera C., Common neural substrates for the addictive properties of nicotine and cocaine, Science 275 (1997) 83-86.
87. [87] Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., MacGregor R., Alexoff D., Shea C., Schlyer D., Wolf A.P., Warner D., Zezulkova I., Cilento R., Inhibition of monoamine oxidase B in the brains of smokers, Nature 379 (1996) 733-736.
88. [88] Henningfield J.E., Miyasato K., Jasinski D.R., Cigarette smokers self-administer intravenous nicotine, Pharmacol. Biochem. Behav. 19 (1983) 887-890.
89. [89] Picciotto M.R., Zoli M., Rimondini R., Léna C., Marubio L.M., Merlo Pich E., Fuxe K., Changeux J.P., Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine, Nature 391 (1998) 173-177.
90. [90] Ochoa E.L., Li L., McNamee M.G., Desensitization of central cholinergic mechanisms and neuroadaptation to nicotine, Mol. Neurobiol. 4 (1990) 251-287.
91. [91] Pidoplichko V., DeBiasi M., Williams J.T., Dani J.A., Nicotine activates and desensitizes midbrain dopamine neurons, Nature 390 (1997) 401-404.
92. [92] Egan T.M., North R.A., Actions of acetylcholine and nicotine on rat locus coeruleus neurons in vitro, Neuroscience 19 (1986) 565-567.
93. [93] Zhu J.J., Ulrich D.J., Nicotinic receptor-mediated responses in relay cells and interneurons in the rat lateral geniculate nucleus, Neuroscience 80 (1997) 191-202.
94. [94] Fenster C.P., Rains M.F., Noerager B., Quick M.W., Lester R.A., Influence of subunit composition on desensitization of neuronal acetylcholine receptors at low concentrations of nicotine, J. Neurosci. 17 (1997) 5747-5759.
95. [95] Futami T., Takakusaki K., Kitai S.K., Glutamatergic and cholinergic inputs from the pedunculopontine tegmental nucleus to dopamine neurons in the substantia nigra pars compacta, Neuroscience Res. 21 (1995) 331-342.
96. [96] Yeomans J., Baptista M., Both nicotinic and muscarinic receptors in ventral tegmental area contribute to brain-stimulation, Pharmacol. Biochem. Behav. 57 (1997) 915-921.
97. [97] Ivanova S., Greenshaw A.J., Nicotine-induced decreases in VTA electrical self-stimulation thresholds: blockade by haloperidol and mecamylamine but not scopolamine or ondansetron, Psychopharmacology 134 (1997) 187-192.
98. [98] Epping-Jordan M.P., Watkins S.S., Koob G.F., Markou A., Dramatic decreases in brain reward function during nicotine withdrawal, Nature 393 (1998) 76-79.
99. [99] Nisell M., Nomikos G.G., Svensson T.H., Nicotine dependence, midbrain dopamine systems and psychiatric disorders, Pharmacol. Toxicol. 76 (1995) 157-162.
100. [100] Levin E.D., Wilson W., Rose J.E., McEvoy J., Nicotine-haloperidol interactions and cognitive performance in schizophrenics, Neuropsychopharmacology 15 (1996) 429-436.
101. [101] Shytle R.D., Silver A.A., Philipp M.K., Mcconville B.J., Sanberg P.R., Transdermal nicotine for Tourette's syndrome, Drug Dev. Res. 38 (1996) 290-298.
102. [102] Levin E.D., Conners C.K., Sparrow E., Hinton S.C., Erhardt D., Meek W.H., Rose J.E., March J., Nicotine effects on adults with attention-deficit/hyperactivity disorder, Psychopharmacology 123 (1996) 55-63.
103. [103] Fagerstrom K.O., Pomerleau O., Giordani B., Stelson F., Nicotine may releive symptoms of Parkinson's disease, Psychopharmacology 116 (1994) 117-119.
104. [104] Clemens P., Baron J.A., Coffey D., Reeves A., The short term effect of nicotine chewing gum in patients with Parkinson's disease, Psychopharmacology 117 (1995) 253-256.
105. [105] Leonard S., Adams C., Breese C.R., Adler L.E., Bickford P., Byerley W., Coon H., Griffith J.M., Miller C., Myles W.M., Nagamoto H.T., Rollins Y., Stevens K.E., Waldo M., Freedman R., Nicotinic receptor function in schizophrenia, Schizophr. Bull. 22 (1996) 431-145.
106. [106] Freedman R., Coon H., Mylesworsley M., Orr Urtreger A., Olincy A., Davis A., Polymeropoulos M., Holik J., Hopkins J., Hoff M., Rosenthal J., Waldo M.C., Reimherr F., Wender P., Yaw J., Young D.A., Breese C.R., Adams C., Patterson D., Adler L.E., Kruglyak L., Leonard S., Byerley W., Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus, Proc. Natl. Acad. Sci. USA 94 (1997) 587-592.
107. [107] McGehee D.S., Heath M.J., Gelber S., Devay P., Role L.W., Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors, Science 269 (1995) 1692-1696.
108. [108] Gray R., Rajan A.S., Radcliffe K.A., Yakehiro M., Dani J.A., Hippocampal synaptic transmission enhanced by low concentrations of nicotine, Nature 383 (1996) 713-716.
109. [109] Chen D.N., Patrick J.W., The alpha-bungarotoxin-binding nicotinic acetylcholine receptors from rat brain contains only the alpha7 subunit, J. Biol. Chem. 272 (1997) 24024-24029.
110. [110] Lefkowitz R.J., Cotecchia S., Samama P., Costa T., Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci. 14 (1993) 303-307.
111. [111] Gomez C.M., Gammack J.T., A leucine-to-phenylalanine substitution in the acetylcholine receptor ion channel in a family with the slow-channel syndrome, Neurology 45 (1995) 982-985.
112. [112] Winzer-Serhan U.K., Leslie F.M., Codistribution of nicotinic acetylcholine receptor subunit alpha3 and beta4 mRNAs during rat brain development, J. Comp. Neurol. 386 (1997) 540-554.